Rigel Pharmaceuticals Receives 'Moderate Buy' Rating from Analysts

Analysts see potential in the biotech company's pipeline despite mixed ratings

Mar. 29, 2026 at 6:13am

Got story updates? Submit your updates here. ›

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has received a consensus 'Moderate Buy' rating from the six analysts currently covering the firm, according to Marketbeat Ratings. Three analysts have a hold recommendation, while three have a buy recommendation, with an average 12-month price target of $45.67.

Why it matters

Rigel Pharmaceuticals is a clinical-stage biotech company focused on developing novel small molecule therapeutics for immune, hematologic and oncologic diseases. The mixed analyst ratings reflect the company's progress and challenges as it works to advance its pipeline and commercialize its lead drug Tavalisse.

The details

The analysts' ratings come as Rigel Pharmaceuticals reported mixed financial results in its latest quarter. While the company saw revenue growth, it missed earnings expectations. Rigel's lead drug Tavalisse, approved for the treatment of chronic immune thrombocytopenia (ITP), has seen steady but slow adoption since its launch.

  • Rigel Pharmaceuticals reported Q1 2026 financial results on March 3, 2026.
  • The company's stock is currently trading at $25.81 as of March 29, 2026.

The players

Rigel Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for immune, hematologic and oncologic diseases.

Tavalisse

Rigel's lead drug product, an oral spleen tyrosine kinase (SYK) inhibitor approved in the U.S. for the treatment of adult patients with chronic immune thrombocytopenia (ITP).

Got photos? Submit your photos here. ›

What they’re saying

“Rigel Pharmaceuticals has a promising pipeline, but the slow adoption of Tavalisse has been a concern for investors.”

— Analyst

What’s next

Investors will be watching to see if Rigel can drive stronger sales of Tavalisse and advance its pipeline of novel drug candidates. The company's next earnings report is expected in early May 2026.

The takeaway

While Rigel Pharmaceuticals faces some challenges, the mixed analyst ratings suggest the company's long-term potential. Its focus on rare and chronic diseases represents an opportunity, but the biotech will need to demonstrate consistent execution to win over more investors.